Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


From Onivyde To OTx: Ipsen Fortifies Oncology with Primary Care Dealmaking

Executive Summary

Ipsen's cash-generating primary care business is supporting a flurry of activity in its larger specialty care franchise. The French pharma has just signed a new deal with Italian company Akkadeas Pharma to give it a boost in primary care.

You may also be interested in...

Ipsen's New CEO Targets At Least One New Drug Annually 'Forever'

The French pharma under its American CEO plans to transform itself through R&D and M&A, and promises to launch at least one new drug or new valuable indication every year - "forever".

Ipsen Shores Up Cash-Generating Primary Care Business With Sanofi CHC Buy

Ipsen has picked up five of Sanofi's consumer healthcare products in certain European markets to enable the larger company's deal with Boehringer Ingelheim to proceed. Despite moves by Ipsen to bolster its cash-generating primary care business, some analysts still believe a sale could make good business sense.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts